In addition, 3M has IRMs available for license in the areas of cancer, asthma/allergy and as vaccine adjuvants.
3M Drug Delivery Systems Vaccine Business Development director Mark Tomai said the molecule offers potential for treating patients that suffer from a variety of dermatologic conditions.
Spirig Pharma CEO Silvio Inderbitzin said they are excited to expand their franchise of dermatology offerings in the prevention and treatment of sun damage-related skin conditions.
"With 3M’s IRM molecule, we can enhance our portfolio with the help of an experienced partner in drug delivery technologies," Inderbitzin said.
